It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The human gastric epithelium forms highly organized gland structures with different subtypes of cells. The carcinogenic bacterium Helicobacter pylori can attach to gastric cells and subsequently translocate its virulence factor CagA, but the possible host cell tropism of H. pylori is currently unknown. Here, we report that H. pylori preferentially attaches to differentiated cells in the pit region of gastric units. Single-cell RNA-seq shows that organoid-derived monolayers recapitulate the pit region, while organoids capture the gland region of the gastric units. Using these models, we show that H. pylori preferentially attaches to highly differentiated pit cells, marked by high levels of GKN1, GKN2 and PSCA. Directed differentiation of host cells enable enrichment of the target cell population and confirm H. pylori preferential attachment and CagA translocation into these cells. Attachment is independent of MUC5AC or PSCA expression, and instead relies on bacterial TlpB-dependent chemotaxis towards host cell-released urea, which scales with host cell size.
The carcinogenic bacterium Helicobacter pylori infects gastric cells. Here, the authors show that H. pylori preferentially infects differentiated cells in the pit region of gastric units, and this relies on bacterial chemotaxis towards host cell-released urea, which scales with host cell size.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Julius Maximilians University of Würzburg, Research Centre for Infectious Diseases, Institute for Molecular Infection Biology, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
2 Helmholtz-Centre for Infection Research (HZI), Helmholtz Institute for RNA-based Infection Research (HIRI), Würzburg, Germany (GRID:grid.498164.6)
3 University of Würzburg, Core Unit Systems Medicine, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
4 Charité Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
5 University Hospital of Würzburg, Department of General, Visceral, Vascular and Paediatric Surgery, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891)
6 Julius Maximilian University of Würzburg and Comprehensive Cancer Center Mainfranken, Institute of Pathology, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
7 Julius Maximilians University of Würzburg, Research Centre for Infectious Diseases, Institute for Molecular Infection Biology, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658); Technische Universität Berlin and Charité–Universitätsmedizin Berlin, Si-M/‘Der Simulierte Mensch’, Berlin, Germany (GRID:grid.6734.6) (ISNI:0000 0001 2292 8254); Technische Universität Berlin, Institute of Biotechnology, Berlin, Germany (GRID:grid.6734.6) (ISNI:0000 0001 2292 8254)